A phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advanced transitional carcinoma of the urothelium.

Trial Profile

A phase II single-arm trial to evaluate cisplatin and gemcitabine chemotherapy in combination with sunitinib for first-line treatment of patients with advanced transitional carcinoma of the urothelium.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2016

At a glance

  • Drugs Sunitinib (Primary) ; Cisplatin; Gemcitabine
  • Indications Urogenital cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SUCCINCT
  • Most Recent Events

    • 10 Apr 2015 Status changed from active, no longer recruiting to completed as per ISRCTN: Current Controlled Trials.
    • 04 Mar 2013 Accrual to date is 100% according to United Kingdom Clinical Research Network.
    • 03 Mar 2013 Planned end date changed from 1 May 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top